Barriers to advancing nanotechnology to better improve and translate nanomedicines

Frontiers of Chemical Science and Engineering

Volumn 8, Issue 3, 2014, Pages 265-275

  Wang, Yuwei ^a   Grainger, David W ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Drug delivery; Nanomedicine; Nanotechnology; Targeted delivery; Therapeutic

Indexed keywords

EID: 84910006053     PISSN: 20950179     EISSN: 20950187     Source Type: Journal    
DOI: 10.1007/s11705-014-1442-x     Document Type: Review

References (75)

1. Etheridge ML, Campbell S A, Erdman A G, Haynes C L, Wolf SM, McCullough J. The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine, 2013, 9: 1–14
2. Bawa R. Nanoparticle-based therapeutics in humans: A survey. Nanotechnology Law & Business, 2008, 5: 135–155
3. Ventola C L. The nanomedicine revolution. Part 2: Current and future clinical applications. Pharmacy and Therapeutics, 2012, 37(10): 582–591
4. Bawa R. Regulating nanomedicine—Can the FDA handle it? Current Drug Delivery, 2011, 8: 227–234
5. Vashist S K, Venkatesh A G, Mitsakakis K, Czilwik G, Roth G, Stetten F, Zengerle R. Nanotechnology-based biosensors and diagnostics: Technology push versus industrial/healthcare requirements. BioNanoScience, 2012, 2: 115–126
6. Robert J, Fisher T P. Form nanoparticles via controlled crystallization. Chemical Engineering Progress, 2008, 33-39
7. Tlmpe C. Drug solubilization strategies applying nanoparticulate formulation and solid dispersion approaches in drug development. Pharmacological Reviews, 2010, 13: 12–21
8. Muller R H, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Advanced Drug Delivery Reviews, 2001, 47: 3–19
9. Merisko-Liversidge E M, Liversidge G G. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicologic Pathology, 2008, 36: 43–48
10. Johnson K C. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility. Journal of Pharmaceutical Sciences, 2012, 101: 681–689
11. Kaptay G. On the size and shape dependence of the solubility of nano-particles in solutions. International Journal of Pharmaceutics, 2012, 430: 253–257
12. Merisko-Liversidge E, Liversidge G G. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Advanced Drug Delivery Reviews, 2011, 63: 427–440
13. Miele E, Spinelli G P, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine, 2009, 4: 99–105
14. Raj S, Jose S, Sumod U S, Sabitha M. Nanotechnology in cosmetics: Opportunities and challenges. Journal of Pharmacy and Bioallied Sciences, 2012, 4: 186–193
15. Wiechers J W, Musee N. Engineered inorganic nanoparticles and cosmetics: Facts, issues, knowledge gaps and challenges. Journal of Biomedical Nanotechnology, 2010, 6: 408–431
16. Mu L, Sprando R L. Application of nanotechnology in cosmetics. Pharm Res, 2010, 27: 1746–1749
17. Nohynek G J, Antignac E, Re T, Toutain H. Safety assessment of personal care products/cosmetics and their ingredients. Toxicology and Applied Pharmacology, 2010, 243: 239–259
18. Ryman-Rasmussen J P, Riviere J E, Monteiro-Riviere N A. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicological Sciences, 2006, 91: 159–165
19. Rouse J G, Yang J, Ryman-Rasmussen J P, Barron A R, Monteiro-Riviere N A. Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Letters, 2007, 7: 155–160
20. Corot C, Warlin D. Superparamagnetic iron oxide nanoparticles for MRI: Contrast media pharmaceutical company R&D perspective. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, 2013, 5(5): 411–422
21. Lodhia J, Mandarano G, Ferris N, Eu P, Cowell S. Development and use of iron oxide nanoparticles (Part 1): Synthesis of iron oxide nanoparticles for MRI. Biomedical Imaging and Intervention Journal, 2010, 6: e12
22. Huang C H, Tsourkas A. Gd-based macromolecules and nanoparticles as magnetic resonance contrast agents for molecular imaging. Current Topics in Medicinal Chemistry, 2013, 13: 411–421
23. Schellenberger E A, Bogdanov A Jr, Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: A nanoparticle for detecting apoptosis by MRI. Molecular Imaging, 2002, 1: 102–107
24. Harisinghani M G, Barentsz J, Hahn P F, Deserno W M, Tabatabaei S, van de Kaa C H, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. The New England Journal of Medicine, 2003, 348: 2491–2499
25. Fortina P, Kricka L J. Nanotechnology: Improving clinical testing? Clinical Chemistry, 2010, 56: 1384–1389
26. Dobson M G, Galvin P, Barton D E. Emerging technologies for point-of-care genetic testing. Expert Review of Molecular Diagnostics, 2007, 7: 359–370
27. Agasti S S, Rana S, Park M H, Kim C K, You C C, Rotello V M. Nanoparticles for detection and diagnosis. Advanced Drug Delivery Reviews, 2010, 62: 316–328
28. Sanvicens N, Marco M P. Multifunctional nanoparticles—properties and prospects for their use in human medicine. Trends in Biotechnology, 2008, 26: 425–433
29. Dandy D S, Wu P, Grainger D W. Array feature size influences nucleic acid surface capture in DNA microarrays. Proceedings of National Academy of Sciences of the United States of America, 2007, 104: 8223–8228
30. Rao A N, Grainger D W. Biophysical properties of nucleic acids at surfaces relevant to microarray performance. Biomaterials Science, 2014, 2: 436–471
31. Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano, 2013, 7: 7442–7447
32. Loeve S, Vincent B B, Gazeau F. Nanomedicine metaphors: From war to care. Emergence of an oecological approach. Nano Today, 2013, 8(6): 560–565
33. Grainger D W, Castner D G. Nanobiomaterials and nanoanalysis: how to improve the nanoscience for biotechnology. Advanced Materials, 2008, 20: 867–877
34. Crist RM, Grossman J H, Patri A K, Stern S T, Dobrovolskaia MA, Adiseshaiah P P, Clogston J D, McNeil S E. Common pitfalls in nanotechnology: Lessons learned from NCI’s nanotechnology characterization laboratory. Integrative Biology, 2013, 5: 66–73
35. Richman E K, Hutchison J E. The nanomaterial characterization bottleneck. ACS Nano, 2009, 3: 2441–2446
36. Buzea C, Pacheco I I, Robbie K. Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases, 2007, 2: MR17–71
37. Baer D R, Engelhard M H, Johnson G E, Laskin J, Lai J, Mueller K, Munusamy P, Thevuthasan S, Wang H, Washton N, Elder A, Baisch B L, Karakoti A, Kuchibhatla S V N T, Moon D. Surface characterization of nanomaterials and nanoparticles: Important needs and challenging opportunities. Journal of Vaccum Science & Technology A, 2013, 31: 50820
38. Stirland D L, Nichols J W, Miura S, Bae Y H. Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice. Journal of Controlled Release, 2013, 172: 1045–1064
39. Begley C G, Ellis L M. Drug development: Raise standards for preclinical cancer research. Nature, 2012, 483: 531–533
40. Ensign L M, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Advanced Drug Delivery Reviews, 2012, 64: 557–570
41. Yamanaka Y J, Leong K W. Engineering strategies to enhance nanoparticle-mediated oral delivery. Journal of Biomaterials Science, Polymer Edition, 2008, 19: 1549–1570
42. Yuan H, Chen C Y, Chai G H, Du Y Z, Hu F Q. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Molecular Pharmaceitocs, 2013, 10: 1865–1873
43. Hussain N, Jaitley V, Florence A T. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Advanced Drug Delivery Reviews, 2001, 50: 107–142
44. Schleh C, Semmler-Behnke M, Lipka J, Wenk A, Hirn S, Schäffler M, Schmid G, Simon U, Kreyling W G. Size and surface charge of gold nanoparticles determine absorption across intestinal barriers and accumulation in secondary target organs after oral administration. Nanotoxicology, 2012, 6(1): 36–46
45. Moghimi S M, Hunter A C, Murray J C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacological Reviews, 2001, 53: 283–318
46. Moghimi S M, Hunter A C, Murray J C. Nanomedicine: Current status and future prospects. FASEB Journal, 2005, 19: 311–330
47. Bae Y H, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. Journal of Controlled Release, 2011, 153: 198–205
48. Kwon I K, Lee S C, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. Journal of Controlled Release, 2012, 164: 108–114
49. Bertrand N, Leroux J C. The journey of a drug-carrier in the body: An anatomo-physiological perspective. Journal of Controlled Release, 2012, 161: 152–163
50. Harris J M, Chess R B. Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery, 2003, 2: 214–221
51. Chambers E, Mitragotri S. Long circulating nanoparticles via adhesion on red blood cells: Mechanism and extended circulation. Experimental Biology and Medicine, 2007, 232: 958–966
52. Rodriguez P L, Harada T, Christian D A, Pantano D A, Tsai R K, Discher D E. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science, 2013, 339: 971–975
53. Fang R H, Hu C M, Zhang L. Nanoparticles disguised as red blood cells to evade the immune system. Expert Opinion on Biological Therapy, 2012, 12: 385–389
54. Florence A T. “Targeting” nanoparticles: The constraints of physical laws and physical barriers. Journal of Controlled Release, 2012, 164: 115–124
55. Gronow J R. Mechanisms of particle movement in porous media. Clay Minerals, 1986, 21: 753–767
56. Pirollo K F, Chang E H. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends in Biotechnology, 2008, 26: 552–558
57. Kirpotin D B, Drummond D C, Shao Y, Shalaby M R, Hong K, Nielsen U B, Marks J D, Benz C C, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Research, 2006, 66: 6732–6740
58. Chauhan V P, Jain R K. Strategies for advancing cancer nanomedicine. Nature Materials, 2013, 12: 958–962
59. Verma S, Miles D, Gianni L, Krop I E, Welslau M, Baselga J, Pegram M, Oh D Y, Diéras V, Guardino E, Fang L, Lu M W, Olsen S, Blackwell K. Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England Journal of Medicine, 2012, 367: 1783–1791
60. Al-Jamal K T. Active drug targeting: Lessons learned and new things to consider. International Journal of Pharmaceutics, 2013, 454: 525–526
61. Lammers T, Kiessling F, Hennink W E, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release, 2012, 161: 175–187
62. Underwood J C, Carr I. The ultrastructure and permeability characteristics of the blood vessels of a transplantable rat sarcoma. The Journal of Pathology, 1972, 107: 157–166
63. Peterson H I, Appelgren K L. Experimental studies on the uptake and rentention of labelled proteins in a rat tumour. European Journal of Cancer, 1973, 9(8): 543–547
64. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 1986, 46: 6387–6392
65. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability: Where is the missing link? Journal of Controlled Release, 2012, 164: 265–275
66. Nichols J W, Bae Y H. EPR: Evidence and fallacy. Journal of Controlled Release, 2014, 190: 451–464
67. Aaron M, Suzanne K L, Russell B, Lee M E, Zwelling L. A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. PLOS ONE, 2013, doi: 10.1371/journal.pone.0063221
68. Prinz F, Schlange T, Asadullah K. Believe it or not: How much can we rely on published data on potential drug targets? Nature Reviews Drug Discovery, 2011, 10: 712
69. American Type Culture Collection Standards Development Organization Workgroup ASN-0002. Cell line misidentification: the beginning of the end. Nature Reviews Cancer, 2010, 10: 441–448
70. Hughes P, Marshall D, Reid Y, Parkes H, Gelber C. The costs of using unauthenticated, over-passaged cell lines: How much more data do we need? Biotechniques, 2007, 43(5): 575, 577–578, 581–582 passim
71. Hartung T. Look back in anger—what clinical studies tell us about preclinical work. Altex, 2013, 30(3): 275–291
72. Peer D, Karp J M, Hong S, Farokhzad O C, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, 2: 751–760
73. Crommelin D J, Florence A T. Towards more effective advanced drug delivery systems. International Journal of Pharmaceutics, 2013, 454: 496–511
74. Venditto V J, Szoka F C Jr. Cancer nanomedicines: So many papers and so few drugs! Advanced Drug Delivery Reviews, 2013, 65: 80–88
75. Paul SM, Mytelka D S, Dunwiddie C T, Persinger C C, Munos B H, Lindborg S R, Schacht A L. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 2010, 9: 203–214